Skip to content
DataLookout
Menu

GC3114BNCT07883928

Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or Older

StatusRecruiting
PhasePhase 2/3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Start date changed from estimate of Oct 2026 to Oct 12, 2026
    • Site details revised
    • Study title shortened, about 2 words
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Evaluation of the immunogenicity of GC3114B
Timeframe: Day 28 following IP vaccination

Secondary (2)

Evaluation of the safety of GC3114B
Evaluation the safety of GC3114B

Arms and interventions

GC3114BExperimental

inactivated, split influenza vaccine

EflueldaActive comparator

Inactivated split influenza vaccine

Biologicals: vaccination of GC3114B, Vaccination of Efluelda

Sites

1 site in 1 country

  • Korea University Guro HospitalSeoul, Seoul, South Korea